Page 54 - 林口醫研部 9月電子報

•Figure 3. DNAPK inhibitor as the potential moderator for immunotherapy to
suppress tumor growth in vivo. (A) Representative photographs of tumor size

(n=4 per treatment group). (B) No significant change in body weight in each

group; expect the M3814 plus anti-PD-L1 antibody plus cisplatin group. (C)
Tumor weight showed consistent result with tumor volume; (D) DNAPK

inhibitor combined with anti-PD-L1 or anti-PD-L1 plus cisplatin could

suppress tumor growth rate in vivo.

(A-D) The statistical significance was analyzed using unpaired t-test. NS, not
significant; PD-L1, programmed cell death protein one pathway. DNAPK,

DNA-dependent protein kinase.

54